13:00
Registration and networking with lunch
13:30
Introduction to Healthcare from Paul Winter, TTP Group
13:40
Welcome from event supporter, Dr Hans Hagen, Cambridge University Health Partners
13:50
Diabetes in the 21st century; still exploring uncharted seas; Dr Tony Coll, Wellcome Trust-MRC Institute of Metabolic Science
The principle of overcoming a hormone deficiency with replacement therapy is a simple one and remains at the heart of diabetes care. However, to do this safely over a long period of time remains difficult for many patients. In particular, there remains the challenge of balancing the avoidance of long term complications of poor glucose control with the need to minimise iatrogenic harm from therapies. In trying to tackle these problems, the diabetes community has always been a ready embracer of technology, both in terms of drug delivery apparatus and biochemical monitoring systems. In this session, I will give a brief overview of both type 1 and type 2 diabetes mellitus and consider some of the medical and financial issues that diabetes care continues to face.
14:10
Q&A
14:15
Remote Continuous Glucose Monitoring (CGM); Melissa Holloway, INPUT Patient Advocacy and Speaking Diabetes Ltd
This talk will provide a whirlwind overview of current diabetes technologies that allow for remote data access, including continuous glucose monitoring, flash glucose monitoring, blood glucose meters with Bluetooth, and cloud-based diabetes data management systems.
14:35
Q&A
14:40
Be all you can be, Always! - integrated mobile connected hardware and software as a service to improve quality of life for people with diabetes; Henrik Norström, Brighter
Brighter has sought to use state of the art technological solutions - such as blood sugar monitors and insulin pens - for diabetes care integrated into a single device, logging the data and transmitting this through a global mobile connection to its platform to close the loop to the different stakeholders in the care chain. With the patients at the epicentre, enabling a higher motivation to adhere to the treatment, we also create the opportunity to empower the patients in relation to the medical condition and the costs. Adherence is low, costs of complications are high. By reducing barriers to effective direct care, adherence should increase and costs of complications should be reduced, resulting in a lower lifecycle cost and high quality of life - Be all you can be, Always!
15:00
Q&A
15:05
Refreshments and networking
15:30
Artificial pancreas – the next step in connectivity and digital treatment of type 1 diabetes; Dr Roman Hovorka, University of Cambridge Metabolic Research Lab
Rapid progress over the past decade has been made with the development of the ‘Artificial Pancreas’, also known as the closed-loop system, which emulates the feedback glucose-responsive functionality of the pancreatic beta cell. The recent FDA approval of the first hybrid closed-loop system makes the Artificial Pancreas a realistic therapeutic option for people with type 1 diabetes. The introduction of the artificial pancreas into clinical practice represents a milestone towards the goal of improving the care of people with type 1 diabetes. There remains a need to understand the impact of the technology, its data remote monitoring capabilities, and implication on current diabetes management and care.
15:50
Q&A
15:55
Disrupting the diabetes integrated care pathway; Dr Sufyan Hussein, Royal Free Hospitals Trust
This talk reviews the current response ecosystem and how technology advancements, integration and data analysis may better support stakeholders and impact care pathways
16:15
Q&A
16:20
Panel session with all speakers chaired by SIG Champion, Paul Winter, TTP Extra Panellist - Stuart Stafford, AstraZeneca
16:50
Event Closes